Anixa Biosciences receives approval of protocol amendment for ovarian cancer CAR-T clinical trial: San Jose, California Friday, February 21, 2025, 18:00 Hrs [IST] Anixa Bioscience ...

Ovarian cancer is one of the deadliest gynaecological cancers, yet there currently is no early diagnostic test. Here’s what you need to know.

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt ...

ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery ...